Speedel announced today the start of its Phase III study for SPP301, its once-a-day oral endothelin A receptor antagonist (ERA) in the indication of diabetic nephropathy (diabetic kidney disease). The ASCEND(1) study has begun with the first patient visit as per the schedule outlined by Speedel in March 2005 when the company reported successful completion [...]
Please fill in the following fields
* - Required
Your Name: *
Your E-Mail: *
Your Remarks:
Friend's Name: *
Friend's E-Mail: *
